How do Angelman syndrome and Prader‑Willi syndrome differ in genetics, clinical presentation, and management?

Angelman vs Prader-Willi Syndrome: Key Differences

Both Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are clinically distinct imprinting disorders affecting the same chromosomal region (15q11-q13) but differ fundamentally in their parent-of-origin: PWS results from loss of paternal gene expression while AS results from loss of maternal gene expression, leading to completely different clinical phenotypes that require syndrome-specific management approaches.

Genetic Mechanisms: Mirror Image Disorders

The genetic architecture reveals why these are considered "sister imprinted disorders" 1, 2:

Prader-Willi Syndrome (PWS)

• >70% cases: Deletion of 15q11-q13 on the paternally contributed chromosome 15
• ~28% cases: Maternal uniparental disomy (UPD) - both chromosome 15s inherited from mother
• <2% cases: Imprinting center defects causing nonexpression of paternal genes
• Candidate genes: SNRPN (codes for small nuclear ribonucleoprotein involved in mRNA splicing) and MAGEL2 are primary candidates 1, 3

Angelman Syndrome (AS)

• ~70% cases: Deletion of 15q11-q13 on the maternally contributed chromosome 15
• 3-5% cases: Paternal UPD
• ~8% cases: Imprinting defects
• 15-20% cases: UBE3A gene mutations or unknown mechanisms
• Causative gene: UBE3A (codes for E6-AP ubiquitin ligase) is the single responsible gene 1, 4

Critical diagnostic point: The same chromosomal deletion produces completely different syndromes depending on which parent contributed the deleted chromosome 1.

Clinical Presentation: Strikingly Different Phenotypes

Prader-Willi Syndrome Features 2, 4, 3

Infancy:

• Severe hypotonia with poor suck reflex
• Failure to thrive
• Feeding difficulties requiring gavage feeding

Childhood to adulthood:

• Hyperphagia developing around age 2-8 years leading to morbid obesity if not externally controlled
• Growth hormone deficiency and short stature
• Hypogonadism/hypogenitalism
• Mild to moderate intellectual disability
• Obsessive-compulsive behaviors
• Hypothalamic insufficiency affecting multiple hormones
• Characteristic facial features (narrow bifrontal diameter, almond-shaped eyes)
• Small hands and feet

Angelman Syndrome Features 2, 4, 3

More severe neurologic impairment:

• Severe intellectual disability (more profound than PWS)
• Absent or severely limited speech (typically <5-10 words)
• Seizures (80-90% of cases)
• Ataxia and tremulous movements
• Inappropriate laughter and happy demeanor ("happy puppet syndrome" - outdated term)
• Microcephaly (often acquired)
• Sleep disturbances
• Characteristic EEG patterns

Key differentiator: AS has much more severe cognitive and neurologic impairment with seizures and ataxia, while PWS has more severe behavioral, endocrine, and metabolic disorders 4.

Diagnostic Testing Algorithm

First-line test for both disorders 1, 5:

Methylation Analysis (DNA Methylation Testing)

• Use methylation-sensitive probes (SNRPN or PW71B) to detect parent-of-origin patterns
• This test detects >99% of PWS cases and ~80% of AS cases
• Interpretation:
  • Only maternal alleles present → PWS confirmed
  • Only paternal alleles present → AS confirmed
  • Biparental inheritance → PWS ruled out; most AS causes ruled out

Subsequent Subtyping (after positive methylation) 1, 6, 5:

To determine mechanism and recurrence risk:

1. FISH with SNRPN probe - detects deletions (~70% of cases for both)
2. Microsatellite/STR linkage analysis - identifies UPD (~28% PWS, 3-5% AS)
3. For AS specifically: If above negative, perform UBE3A sequencing to detect mutations (~10% of AS cases)

Important caveat: 15-20% of AS cases will test negative on all standard testing and require referral to specialized research laboratories 1.

Modern Approach 7

Long-read nanopore sequencing can now detect and subtype PWS/AS in a single test without requiring parental samples, including detection of heterodisomy, isodisomy, deletion types, and UBE3A mutations.

Management Differences

Prader-Willi Syndrome Management 2, 3

Infancy:

• Aggressive feeding support (gavage feeding often required)
• Early growth hormone therapy (improves body composition, muscle tone, linear growth)

Childhood onward:

• Strict environmental control of food access - locked kitchens, supervised meals (critical for preventing life-threatening obesity)
• Growth hormone continuation
• Sex hormone replacement for hypogonadism
• Treatment of hypothalamic insufficiency
• Behavioral interventions for obsessive-compulsive symptoms
• Structured environment with consistent routines

Angelman Syndrome Management 2, 3

Focus on neurologic and developmental support:

• Antiepileptic medications for seizure control (present in 80-90%)
• Physical therapy for ataxia and motor dysfunction
• Augmentative and alternative communication (AAC) devices (since speech is severely limited)
• Sleep disorder management
• Behavioral interventions for hyperactivity
• Orthopedic monitoring for scoliosis

Critical difference: PWS requires lifelong strict dietary control and metabolic/endocrine management, while AS requires intensive neurologic management with seizure control and communication support 2, 4.

Recurrence Risk Counseling

Deletion cases (most common): Low recurrence risk (~1% or less) - typically de novo events 1

UPD cases: Very low recurrence risk - random event during meiosis 1

Imprinting center defects:

• If deletion of IC detected: 50% recurrence risk (inherited)
• If no IC deletion found: Low recurrence risk (likely epimutation) 1

AS with UBE3A mutation: 50% recurrence risk if maternally inherited 1

Essential point: Molecular subtyping is critical for accurate genetic counseling, as recurrence risks vary dramatically from <1% to 50% depending on mechanism 1, 6.

Common Diagnostic Pitfalls

1. Relying on karyotype alone: High-resolution chromosome analysis is insufficient and will miss most cases 1

2. Not performing methylation analysis first: This should be the initial test, not FISH or microarray alone 1, 5

3. Stopping workup after negative initial testing in AS: Remember 15-20% of AS cases require UBE3A sequencing or research laboratory referral 1

4. Assuming clinical diagnosis is sufficient: Both disorders can be difficult to diagnose clinically, especially in early childhood - molecular confirmation is essential 1, 2

5. Not determining molecular subtype: This is critical for recurrence risk counseling and may have prognostic implications 6, 5